DUBLIN--(BUSINESS WIRE)--The "Reversible Anticholinesterases -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Reversible Anticholinesterases - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Reversible Anticholinesterases development.
Descriptive coverage of pipeline development activities for Reversible Anticholinesterases - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Reversible Anticholinesterases pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Reversible Anticholinesterases - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Reversible Anticholinesterases
4. Comparative Analysis
5. Reversible Anticholinesterases Pipeline Products in Clinical Stages
- Product Description
- Research and Development
- Product Development Activities
6. Reversible Anticholinesterases Pipeline Products in Non-clinical Stages
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
- Product Description
- Research and Development
- Product Development Activities
-
Reason for dormancy/discontinuation
Companies Mentioned
- Axovant Sciences
- DeuteRx
- Luye Pharma
- Raptor Pharmaceutical Corp
- Anavex Life Sciences
- Astellas Pharma
- Novartis
- Eisai Co Ltd
- Janssen Pharmaceutical KK
